Liver cirrhosis
D Schuppan, NH Afdhal - The Lancet, 2008 - thelancet.com
Cirrhosis is defined as the histological development of regenerative nodules surrounded by
fibrous bands in response to chronic liver injury, which leads to portal hypertension and end …
fibrous bands in response to chronic liver injury, which leads to portal hypertension and end …
[HTML][HTML] KASL clinical practice guidelines: management of hepatitis C
Korean Association for the Study of the … - Clinical and …, 2016 - ncbi.nlm.nih.gov
Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …
[图书][B] Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15
World Health Organization - 2015 - books.google.com
These are the first World Health Organization (WHO) guidelines for the prevention care and
treatment of persons living with CHB infection and complement similar recent published …
treatment of persons living with CHB infection and complement similar recent published …
[PDF][PDF] Chronic hepatitis B
ASF Lok, BJ McMahon - Hepatology, 2007 - Wiley Online Library
These guidelines have been written to assist physicians and other health care providers in
the recognition, diagnosis, and management of patients chronically infected with the …
the recognition, diagnosis, and management of patients chronically infected with the …
[HTML][HTML] A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Background Entecavir is a potent and selective guanosine analogue with significant activity
against hepatitis B virus (HBV). Methods In this phase 3, double-blind trial, we randomly …
against hepatitis B virus (HBV). Methods In this phase 3, double-blind trial, we randomly …
[PDF][PDF] Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naive patients is rare through 5 years of therapy
DJ Tenney, RE Rose, CJ Baldick, KA Pokornowski… - …, 2009 - Wiley Online Library
Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose
benefits of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance …
benefits of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance …
[PDF][PDF] Antiviral drug‐resistant HBV: standardization of nomenclature and assays and recommendations for management
Substantial advances have been made in the treatment of chronic hepatitis B in the past
decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and …
decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and …
[PDF][PDF] Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
W Yeo, PJ Johnson - Hepatology, 2006 - Wiley Online Library
It is estimated conservatively that more than one third of the world's population has been
infected with the hepatitis B virus (HBV) and that there are 350 million people with chronic …
infected with the hepatitis B virus (HBV) and that there are 350 million people with chronic …
[HTML][HTML] Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of …
More than 360 million persons worldwide (6% of the world population) are chronically
infected by the hepatitis B virus (HBV). Although the incidence of HBV infection has …
infected by the hepatitis B virus (HBV). Although the incidence of HBV infection has …
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
M Sherman, C Yurdaydin, J Sollano, M Silva, YF Liaw… - Gastroenterology, 2006 - Elsevier
Background & Aims: Lamivudine treatment is associated with frequent development of
resistant hepatitis B virus (HBV) and loss of treatment benefit. In preclinical and phase II …
resistant hepatitis B virus (HBV) and loss of treatment benefit. In preclinical and phase II …